These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 11181800

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR, Rall SC, Brennan SO, Nye ER, George PM, Janus ED, Weisgraber KH.
    J Lipid Res; 1990 Mar; 31(3):535-43. PubMed ID: 2341812
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression.
    van Dijk KW, van Vlijmen BJ, de Winther MP, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH.
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2945-51. PubMed ID: 10591674
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease.
    Marais AD.
    Pathology; 2019 Feb; 51(2):165-176. PubMed ID: 30598326
    [Abstract] [Full Text] [Related]

  • 10. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2.
    Huang Y, Rall SC, Mahley RW.
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2817-24. PubMed ID: 9409260
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.
    Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL, Weisgraber KH.
    Nat Struct Biol; 1996 Aug; 3(8):718-22. PubMed ID: 8756331
    [Abstract] [Full Text] [Related]

  • 16. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity.
    Dong LM, Innerarity TL, Arnold KS, Newhouse YM, Weisgraber KH.
    J Lipid Res; 1998 Jun; 39(6):1173-80. PubMed ID: 9643348
    [Abstract] [Full Text] [Related]

  • 17. Impaired secretion of apolipoprotein E2 from macrophages.
    Fan D, Qiu S, Overton CD, Yancey PG, Swift LL, Jerome WG, Linton MF, Fazio S.
    J Biol Chem; 2007 May 04; 282(18):13746-53. PubMed ID: 17341585
    [Abstract] [Full Text] [Related]

  • 18. Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.
    Tavori H, Fan D, Giunzioni I, Zhu L, Linton MF, Fogo AB, Fazio S.
    J Lipid Res; 2014 Oct 04; 55(10):2073-81. PubMed ID: 25183802
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.